Synced daily from ClinicalTrials.gov via AACT. Last sync: .
16 Povorcitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Healthy Participants & Hidradenitis Suppurativa (HS)) and 4,737 total planned enrollment. 8 Phase 3 Povorcitinib trials and 3 Phase 2 are listed. 4 Povorcitinib clinical trials are actively recruiting at 86 U.S. sites across 27 states. Most recent activity: NCT07213973 (Mar 2028).
Where to Participate: All Povorcitinib Trial Sites in the U.S. (86 sites across 27 states)
Every actively recruiting Povorcitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
16 Povorcitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 7 are marked completed.
Are Povorcitinib clinical trials recruiting in 2026?
Yes — 4 Povorcitinib trials are actively recruiting in 2026, with 86 U.S. sites across 27 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Povorcitinib being studied for?
Povorcitinib is being studied for Healthy Participants, Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis, Moderate to Severe Asthma and 6 more. The trials are grouped by indication on this page.
What phase is Povorcitinib in?
Povorcitinib clinical trials span 8 Phase 3, 3 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Povorcitinib clinical trials?
The lead sponsor across the most Povorcitinib trials is Incyte Corporation. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Povorcitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.